Annual Meeting of the NCI Cohort Consortium (Abstract Submission)

Filter submissions
17 submissions
# Created User IP address Presenter's First Name: Presenter's Last Name: Title (eg: professor, assistant professor, chair, etc): Degree(s) Contact Email: Organization: Project Title: Additional Authors Abstract: Operations
17 Fri, 09/13/2024 - 23:04 Anonymous 10.208.24.118 Jongeun Rhee Research Fellow ScD, MS jongeun.rhee@nih.gov NCI/DCEG Serum concentrations of per- and polyfluorinated substances and risk of non-Hodgkin lymphoma
  1. First Name: Jani
    Last Name: Koponen
    Degree(s): MSc
    Organization: Finnish Institute of Health and Welfare
  2. First Name: Joshua
    Middle Initial: N
    Last Name: Sampson
    Degree(s): PhD, MS
    Organization: NCI/DCEG
  3. First Name: Alexander
    Middle Initial: P
    Last Name: Keil
    Degree(s): PhD, MSPH
    Organization: NCI/DCEG
  4. First Name: Mary
    Middle Initial: H
    Last Name: Ward
    Degree(s): PhD
    Organization: NCI/DCEG
  5. First Name: Jonathan
    Middle Initial: N
    Last Name: Hofmann
    Degree(s): PhD, MPH
    Organization: NCI/DCEG
  6. First Name: Wen-Yi
    Last Name: Huang
    Degree(s): PhD, MSPH
    Organization: NCI/DCEG
  7. First Name: Debra
    Middle Initial: T
    Last Name: Silverman
    Degree(s): ScD, ScM
    Organization: NCI/DCEG
  8. First Name: Panu
    Last Name: Rantakokko
    Degree(s): PhD
    Organization: Finnish Institute of Health and Welfare
  9. First Name: Mark
    Middle Initial: P
    Last Name: Purdue
    Degree(s): PhD
    Organization: NCI/DCEG
 Per- and polyfluoroalkyl substances (PFAS) are persistent organic pollutants detectable in the serum of most U.S. adults. Some studies of highly-exposed individuals have suggested positive associations between PFAS and non-Hodgkin lymphoma (NHL). To investigate whether associations exist at lower exposure levels, we conducted a nested case-control study investigating serum PFAS and NHL within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. We measured pre-diagnostic serum concentrations of five PFAS among 706 cases and 706 matched controls. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) for PFAS in relation to NHL, overall and for histologic subtypes [diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL)] using conditional logistic regression. We found no evidence of a positive association with NHL for any of the five PFAS. In analyses of histologic subtypes, perfluorohexane sulfonate (PFHxS) was significantly associated with DLBCL in a model adjusting for all other PFAS (OR for highest vs. lowest quintile =2.19, 95% CI=1.21, 3.95; Ptrend=0.02), but not without mutual adjustment (OR=1.37, 95% CI=0.82, 2.29; Ptrend=0.26). We also observed an inverse association between perfluorononanoate and DLBCL (mutually-adjusted OR=0.83, 95% CI=0.69, 0.99 per doubling in concentration), although the association was only apparent among those with blood drawn in 1997 or later (Pinteraction=0.0003). In conclusion, our findings from a prospective cohort study with PFAS concentrations comparable to the general population do not support an association with increased risk of NHL overall. The suggestive positive association between PFHxS and DLBCL warrants further investigation.
16 Fri, 09/13/2024 - 19:24 Anonymous 10.208.28.69 Liliana Gomez-Flores-Ramos Proffesor Ph.D. liliana.gomez@insp.mx CONAHCyT – Center for Research on Population Health, National Institute of Public Health, Cuernavaca, Morelos, Mexico Leveraging existing cohort studies of Mexican women to better understand Hispanic health
  1. First Name: Dalia
    Last Name: Stern
    Degree(s): Ph.D.
    Organization: CONAHCyT – Center for Research on Population Health, National Institute of Public Health, Cuernavaca, Morelos, Mexico
  2. First Name: Liliana
    Last Name: Gomez-Flores-Ramos
    Degree(s): Ph.D.
    Organization: CONAHCyT – Center for Research on Population Health, National Institute of Public Health, Cuernavaca, Morelos, Mexico
  3. First Name: Briton
    Last Name: Trabert
    Degree(s): Ph.D.
    Organization: Department of Obstetrics and Gynecology, University of Utah, and Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.
  4. First Name: Loïc
    Last Name: Loïc Le Marchand
    Degree(s): Ph.D.
    Organization: University of Hawaii Cancer Center, Honolulu, HI, USA.
  5. First Name: Henry
    Last Name: Gomez
    Degree(s): Ph.D.
    Organization: Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  6. First Name: Paul
    Middle Initial: A
    Last Name: Scheet
    Degree(s): Ph.D.
    Organization: Department of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
  7. First Name: Martin
    Last Name: Lajous
    Degree(s): M.D., DPH
    Organization: Center for Research on Population Health, National Institute of Public Health, Cuernavaca, Morelos, Mexico and Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  8. First Name: V Wendy
    Last Name: Setiawan
    Degree(s): Ph.D.
    Organization: Department of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
  9. First Name: Humberto
    Last Name: Parada Jr.
    Degree(s): Ph.D.
    Organization: Division of Epidemiology and Biostatistics, School of Public Health, San Diego State University, San Diego, CA, USA.
  10. First Name: Amber
    Last Name: Prizada
    Degree(s): Ph.D.
    Organization: University of Illinois at Chicago
  11. First Name: Leslie
    Middle Initial: V
    Last Name: Farland
    Degree(s): Ph.D.
    Organization: Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA.
 Background: The underrepresentation of Hispanics in epidemiologic research is a significant gap in our understanding of health disparities. We aimed to compare the distribution of cancer risk factors among Hispanic women of Mexican heritage (HWMH) participating in existing cohorts to explore the possibility of future data-pooling efforts.

Methods: We used baseline data of HWMH from three US-based studies, the Mexican American Cohort (MAC; n=19,797; 2001-17), the Multiethnic Cohort (MEC; n=18,007; 1993-96), and the Hispanic Community Health Study/Study of Latinos (HCHS/SOL; n=4,022; 2008-2011), and one from Mexico, the Mexican Teachers’ Cohort (MTC; n=115,275; 2006-08).

Results: Participants in MEC (60y) were older on average than MAC (41y), HCHS/SOL (46y), and MTC (43y) at enrollment. Most MAC (78%) and HCHS/SOL (85%) participants spoke Spanish as their primary language. Age at menarche (13y), age at menopause (46-48y), and smoking prevalence (~10%) were similar across studies. Parity was higher in MAC (3.8) and MEC (4.1) compared to HCHS/SOL (3.2) and the MTC (2.5). Ever use of oral contraceptives was more frequent in HCHS/SOL (64%) compared to MTC (46%), MAC (38%), and MEC (35%). Obesity, diabetes, and hypertension were more common in the US cohorts.

Conclusion: This work demonstrates the ability to pool NCI Cohort Consortium data to evaluate cancer risk factors in HWMH, an underrepresented group in cancer research. Similarities and differences in characteristics across cohorts can be leveraged to better understand health disparities in HWMH.
15 Fri, 09/13/2024 - 19:13 Anonymous 10.208.28.69 Jung Hye Kwon Professor MD, PhD kwonjhye.onco@gmail.com Chungnam National University College of Medicine/Chungnam National University Sejong Hospital Quality of life follow-up cohort of patients with incurable cancer and their caregivers attending regional cancer centers - study protocol/HA23C042723C042
  1. First Name: Jung Hun
    Last Name: Kang
    Organization: Division of Hematology/Oncology Department of Internal Medicine School of Medicine, Gyeongsang National University
  2. First Name: Kyu-Hyoung
    Last Name: Lim
    Organization: Department of Internal Medicine, Kangwon National University Hospital
  3. First Name: Jung Sik
    Last Name: Huh
    Organization: Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea 4. Department of Urology, School of Medicine
  4. First Name: Eun-Kee
    Last Name: Song
    Organization: Division of Hematology/Oncology, Chonbuk National University Medical School
  5. First Name: Young-Jin
    Last Name: Choi
    Organization: Department of Internal Medicine, Pusan National University Hospital
  6. First Name: Ye-Seul
    Last Name: Kim
    Organization: Department of Family Medicine, Chungbuk National University Hospital
  7. First Name: Byung Ho
    Last Name: Choi
    Organization: Ulsan University Hospital, University of Ulsan College of Medicine
  8. First Name: Hyun Woo
    Last Name: Lee
    Organization: Department of Hematology-Oncology, Ajou University School of Medicine
  9. First Name: Hwan Jung
    Last Name: Yun
    Organization: Department of Internal Medicine, Chungnam National University Hospital
  10. First Name: Su-Jin
    Last Name: Koh
    Organization: Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea
  11. First Name: Sun Jin
    Last Name: Sym
    Organization: Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital
  12. First Name: Se-il
    Last Name: Go
    Organization: Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine
 Introduction: Cancer patients experience physical, mental, and social pain, impacting both the patient and their family. Increasing cancer incidence and advances in treatment both increase the number of cancer survivors in Korea. Because patients flock to Seoul and the metropolitan areas, continuous care and comprehensive life support are lacking. Traveling long distances for treatment causes logistical and quality-of-life challenges for patients traveling for care. Method: This prospective cohort study targets incurable cancer patients (n=720) and their families (n=288) from ten regional cancer centers and two affiliated hospitals in Korea. Sub-cohorts are based on treatment refusal, Neurologic complications, catheter-related symptoms, and skeletal-related events. Medical records and patient-reported outcomes will be collected every three months up to three years following, with surveys for guardians conducted for a year post-patient demise. Discussion: Cancer's dynamic nature significantly affects both patients and their caregivers. Identifying factors impacting their quality of life is crucial for integrating them healthily into society. The establishment of a regional cancer center consortium, guided by the findings of this study, aims to address and improve the unmet needs of local cancer patients and their families, enhancing overall quality of life and contributing to the well-being of our local community. Trial registration: KCT0009177 (registered at https://cris.nih.go.kr/ on 2024/02/16)
This study was supported by the National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (RS-2023-CC138341).
Key Words: Cancer, regional cancer center, catheter, SRE, Quality of life
14 Fri, 09/13/2024 - 19:03 Anonymous 10.208.24.118 Liliana Gomez-Flores-Ramos Professor Ph.D. liliana.gomez@insp.mx CONAHCYT-National Institute of Public Health, Mexico Added Sugar Intake and Breast Cancer Risk: Findings from the Mexican Teachers' Cohort
  1. First Name: Leticia
    Last Name: Palma
    Degree(s): Ph.D.
    Organization: National Institute of Public Health
  2. First Name: Dalia
    Last Name: Stern
    Degree(s): Ph.D.
    Organization: CONAHCYT-National Institute of Public Health
  3. First Name: Marion
    Last Name: Brochier
    Degree(s): M.D., MPH
    Organization: National Institute of Public Health
  4. First Name: Adrian
    Last Name: Cortes-Valencia
    Degree(s): MPH
    Organization: National Institute of Public Health
  5. First Name: Adriana
    Last Name: Monge
    Degree(s): MPH
    Organization: National Institute of Public Health
  6. First Name: Laura
    Last Name: Quezada
    Degree(s): Ph.D.
    Organization: National Institute of Public Health
  7. First Name: Martin
    Last Name: Lajous
    Degree(s): M.D., DPH
    Organization: National Institute of Public Health, Harvard
 Background: Mexico has a high consumption of added sugars (AS), and previous have suggested a potential link between carbohydrate intake and breast cancer (BC) incidence in Mexico. However, this association has not been confirmed in a prospective study. We aimed to estimate the effect of AS intake on BC in the Mexican Teachers’ Cohort.

Methods: We assessed diet in 89,879 BC-free women using a validated FFQ in the 2006-2008 baseline assessment. We estimated AS using a standardized procedure. BC diagnoses from baseline to December 2019 were validated using electronic health records and cancer and mortality registries. The data was analyzed using adjusted multivariable Cox regression models and AS was modeled with restricted cubic splines. Women were categorized based on their daily AS intake (< 31 g/d, 31-60 g/d, 61-90 g/d, and over 91 g/day) as per the EAT-Lancet recommendation. We calculated the estimates for overall, premenopausal, and postmenopausal BC.

Results: The median AS intake was 52g/day (IQR 36-77), and 1,313 BC cases were confirmed over a median follow-up of 10.9 years. Overall, a nonlinear dose-response relationship with limited HR elevation was observed. For premenopausal BC, HR peaked at 1.4 and remained relatively stable after 50g/day. Compared to women in the lowest category of AS (≤31 g/day), women in the highest category (≥ 91g/day) had a higher incidence of BC (HR=1.34, 95%CI 0.93, 1.92). No significant increase was observed for postmenopausal women.

Conclusion: Our findings suggest that AS may play a role in the incidence of premenopausal BC in Mexican women.
13 Fri, 09/13/2024 - 16:50 Anonymous 10.208.28.69 Martin Lajous Faculty-Researcher MD, ScD mlajous@insp.mx Instituto Nacional de Salud Publica An Efficient Pipeline-Based Geocoding Approach to Handle Self-Reported Addresses in a Large Population-based Cancer Cohort in Mexico
  1. First Name: Alejandro
    Last Name: Molina-Villegas
    Degree(s): PhD
    Organization: CONAHCyT-CentroGeo
  2. First Name: Karla
    Last Name: Valdez-Trejo
    Degree(s): MS
    Organization: Instituto Nacional de Salud Publica
  3. First Name: Pablo
    Last Name: Lopez-Ramires
    Degree(s): PhD
    Organization: CentroGeo
  4. First Name: Alberto
    Last Name: Simpser
    Degree(s): PhD
    Organization: ITAM
  5. First Name: Adrian
    Last Name: Cortes-Valencia
    Degree(s): MS
    Organization: Instituto Nacional de Salud Publica
  6. First Name: Dalia
    Last Name: Stern
    Degree(s): PhD
    Organization: CONAHCyT-Instituto Nacional de Salud Publica
  7. First Name: Karla
    Last Name: Cervantes-Martinez
    Degree(s): PhD
    Organization: Instituto Nacional de Salud Publica
  8. First Name: Liliana
    Last Name: Gomez-Flores-Ramos
    Degree(s): PhD
    Organization: Instituto Nacional de Salud Publica
 Background. Geocoding participants’ addresses in epidemiologic cohorts is now highly accurate in high-income countries. Non-standardized address notation, lack of address registries, and limitations on geocoding resources are important challenges for geocoding in limited resource settings. We aimed to develop an efficient pipeline-based geocoding approach to handle self-reported addresses from participants in a cancer cohort in Mexico, assess the validity of coordinate assignment, and maximize geocoding success.

Methods. We obtained self-reported addresses at baseline in 2006-2008 from 104,003 participants in the Mexican Teachers’ Cohort (n=115,275). After cleaning and standardization, we optimized processing times by splitting the data (651,668 candidate coordinates) and creating 105 Amazon AWS virtual machines to submit queries asynchronously to the ArcGIS REST API. We conducted geospatial verification by projecting candidate coordinates through spatial join operation on Mexico’s official neighborhood vector shapefile. We compared similarities between the self-reported and API-derived addresses using string alignment scoring metrics. To assess accuracy of the procedure we compared address coordinates to residential block-centroid coordinates available in the 2006 national voting registry database.

Results. After discarding non-valid coordinates and conducting geospatial verification and similarity scoring, we assigned coordinates to 101,704 study participants. When we compared assigned coordinates to voting registry block-centroid coordinates for 81,270 participants, the median distance between coordinates was 0.17 km (inter quartile range, 0.06-0.77). We maximized geocoding to 111,299 (97%) study participants by assigning voting registry-defined coordinates to 9,595 participants without a valid address.

Conclusions. Address-level geocoding based on self-reported addresses can be efficiently achieved in large-scale epidemiological studies in Mexico.
12 Fri, 09/13/2024 - 14:24 Anonymous 10.208.28.69 Benjamin Cairns Dr Ph.D. Ben.Cairns@ourfuturehealth.org.uk Our Future Health Our Future Health: A New Prospective Cohort for Translational Research
  1. First Name: Michael
    Middle Initial: B
    Last Name: Cook
    Degree(s): Ph.D.
    Organization: Our Future Health
  2. First Name: David
    Middle Initial: J
    Last Name: Hunter
    Degree(s): M.B.B.S. MPH Sc.D.
    Organization: University of Oxford; Our Future Health
  3. First Name: Raghib
    Last Name: Ali
    Degree(s): M.D. MPH
    Organization: Our Future Health
 Background: Our Future Health is a new UK-wide prospective cohort study supported by the UK Government, industry and charity sectors. Our objective is to recruit 5 million adult residents of the UK to facilitate aetiologic and translational health research, aiming to discover and test more effective approaches to prevention, earlier detection and treatment of diseases.

Methods: The sampling frame for Our Future Health is the total UK adult population. Through invitations and open enrolment, we aim to recruit a cohort that reflects the diversity of the UK population in terms of age, ethnicity, socioeconomic status and geography. Participants complete a questionnaire and attend an appointment for physical measurements and blood sampling, and are genotyped using a custom array with a genome-wide backbone for imputation and extensive coverage of disease- and phenotype-associated variants. Priority data linkages include primary and secondary care records, and cancer and death registrations, in each of the four UK nations.

Results: To date, 1.8 million participants have consented to join Our Future Health, of which 1.3 million have completed the broad baseline questionnaire and over 1 million have donated blood for genotyping and biobanking of plasma, buffy coat and DNA.

Discussion: Key translational aspects of the study include the forthcoming ability for study proposals to request access to baseline blood samples, and for investigator-led recontact studies to recruit participants based on demographics, phenotypes, genotypes or disease risk for risk-stratified research. Our Future Health (ourfuturehealth.org.uk) is already open for data access study proposals.
11 Fri, 09/13/2024 - 11:40 Anonymous 10.208.24.118 Valeria Elahy Postdoctoral Fellow PhD valeria.elahy@cancer.org American Cancer Society Post-diagnosis Adherence to American Cancer Society Guidelines and Mortality Among Prostate Cancer Patients in the Cancer Prevention Study-II Nutrition Cohort
  1. First Name: Valeria
    Last Name: Elahy
    Degree(s): PhD
    Organization: American Cancer Society
  2. First Name: Christina
    Last Name: Newton
    Degree(s): MSPH
    Organization: American Cancer Society
  3. First Name: Alpa
    Last Name: Patel
    Degree(s): PhD
    Organization: American Cancer Society
  4. First Name: Marji
    Last Name: McCullough
    Degree(s): ScD, RD
    Organization: American Cancer Society
  5. First Name: Lauren
    Last Name: Teras
    Degree(s): PhD
    Organization: American Cancer Society
  6. First Name: Clara
    Last Name: Bodelon
    Degree(s): PhD
    Organization: American Cancer Society
  7. First Name: Caroline
    Last Name: Um
    Degree(s): PhD, MPH, RD
    Organization: American Cancer Society
  8. First Name: Erika
    Last Name: Rees-Punia
    Degree(s): PhD, MPH
    Organization: American Cancer Society
  9. First Name: Laura
    Last Name: Mararoff
    Degree(s): DO
    Organization: American Cancer Society
  10. First Name: Ying
    Last Name: Wang
    Degree(s): PhD, MS
    Organization: American Cancer Society
 Purpose: The American Cancer Society (ACS) Guidelines on Nutrition and Physical Activity for Cancer Survivors recommend avoiding obesity, engaging in regular physical activity, following a healthy diet, and limiting alcohol intake. This study aimed to assess the association between adherence to these guidelines and all-cause mortality, cardiovascular disease mortality (CVDM), and prostate cancer-specific mortality (PCSM) among prostate cancer patients and to explore whether the association varies by tumor aggressiveness.

Methods: Data from 4,232 prostate cancer patients in the Cancer Prevention Study-II Nutrition Cohort were analyzed. Adherence to ACS guidelines was scored (0-8), with higher scores indicating greater adherence. Multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for mortality were calculated using Cox proportional hazards regression models.

Results: Higher ACS guideline score was associated with lower risk of all-cause mortality (HR for score 6-8 vs. 0-3: 0.77; 95% CI, 0.69 to 0.85), CVDM (HR: 0.75; 95% CI, 0.63 to 0.91), and PCSM (HR: 0.79; 95% CI, 0.60 to 1.03). Among patients with non-aggressive tumors, higher adherence was associated with significantly lower all-cause mortality (HR: 0.78; 95% CI, 0.70 to 0.87) and CVDM (HR: 0.79; 95% CI, 0.65 to 0.98) but not PCSM. A higher score was associated with lower all-cause mortality (HR: 0.75; 95% CI, 0.58 to 0.95) but not CVDM or PCSM among men with aggressive tumors.

Conclusion: Adherence to ACS guidelines was associated with lower all-cause mortality and CVDM in prostate cancer patients, particularly those with non-aggressive tumors. These findings emphasize the potential benefit of post-diagnosis lifestyle modifications.
10 Fri, 09/13/2024 - 09:05 Anonymous 10.208.28.69 Karine Alcala M.S alcalak@iarc.who.int International Agency for Research on Cancer Smoking history and lung cancer risk on four continents – Comprehensive analysis in 3,000,000 cohort participants from the Lung Cancer Cohort Consortium (LC3)
  1. First Name: Xiaohsuang
    Last Name: Feng
    Degree(s): Ph.D
    Organization: International Agency for Research on Cancer
  2. First Name: Mattias
    Last Name: Johansson
    Degree(s): Ph.D
    Organization: International Agency for Research on Cancer
  3. First Name: Hilary
    Middle Initial: A
    Last Name: Robbins
    Degree(s): Ph.D
    Organization: International Agency for Research on Cancer
 Background

The extent to which lung cancer risk varies between individuals with similar smoking history in different parts of the world has not been described, nor has there been a comprehensive assessment of the importance of age at smoking initiation and cessation.

Methods

The study was conducted in 25 cohorts taking part in the Lung Cancer Cohort Consortium (LC3) and included longitudinal data on 2,879,895 participants from North America, Europe, Oceania, and Asia. We analyzed 38,722,397 person-years of follow-up during which 53,020 participants were diagnosed with lung cancer. We used Cox proportional hazards models to evaluate the association between lung cancer risk and age at smoking initiation and cessation, and flexible parametric survival models to estimate absolute risks of lung cancer.

Results

We found that age at smoking initiation is inversely associated with lung cancer risk, independently of differences in smoking intensity and duration, with 2.2-fold higher risk among those initiating smoking at age 15 or younger compared with those initiating after age 27. Lung cancer risk was much lower in individuals who quit smoking, and reached risk levels close to participants who never smoked among those who quit before age 30. North American participants had modestly higher 5-year risks than did participants in Asia and Europe.

Discussion/Conclusion

This comprehensive analysis highlights the consequence of elevated lung cancer risk for individuals who are exposed to tobacco smoking at an early age, as well as the importance of ceasing tobacco exposure as early as possible.
9 Fri, 09/13/2024 - 06:04 Anonymous 10.208.24.118 Martin Lajous Faculty-Researcher MD, ScD mlajous@insp.mx Instituto Nacional de Salud Publica A casual framework to account for COVID-19 deaths in mortality analyses in large cohort studies.
  1. First Name: Adrian
    Last Name: Cortes-Valencia
    Degree(s): SM
    Organization: Instituto Nacional de Salud Publica
  2. First Name: Liliana
    Last Name: Gomez-Flores-Ramos
    Degree(s): PhD
    Organization: Instituto Nacional de Salud Publica
  3. First Name: Marion
    Last Name: Brochier
    Degree(s): MPH
    Organization: Instituto Nacional de Salud Publica
  4. First Name: Dalia
    Last Name: Stern
    Degree(s): PhD
    Organization: Instituto Nacional de Salud Publica
  5. First Name: Malgorzata
    Last Name: Szpakowicz
    Degree(s): MPH
    Organization: M. Sklodowska-Curie Institute - Oncology Center
  6. First Name: Adriana
    Last Name: Baluta
    Degree(s): MPH
    Organization: M. Sklodowska-Curie Institute - Oncology Center
  7. First Name: Marta
    Last Name: Manczuk
    Degree(s): PhD
    Organization: M. Sklodowska-Curie Institute - Oncology Center
 Background. COVID-19 deaths pose a methodological challenge for epidemiologic cohorts aimed at identifying risk factors for cancer and chronic disease mortality. The pandemic introduced a competing event which can potentially obscure the signals between exposures and chronic disease mortality and complicate the interpretation of results.

Methods. Using a causal framework, we will characterize the causal effects of lifestyle and reproductive factors and the conditions under which they can be identified in a setting where COVID-19 deaths act as a competing event for cancer and chronic disease mortality. We will apply this framework to data from two large cohort studies: the Polish Cohort Study (PONS; n=13,148 women and men) and the Mexican Teachers' Cohort (MTC; n=115,275 women).

Results. By the end of 2022, the proportion of deaths attributed to COVID-19 was 8.3% in the PONS cohort and 10.1% in the MTC cohort. Causal diagrams were used to explicitly articulate causal effects estimated in the presence of COVID-19 deaths as well causal effects that can be estimated using contemporary causal inference methods. Different analytic approaches using mortality follow-up data up to 2023 for both cohorts will illustrate how risk factor mortality estimates vary and how these variations impact interpretation.

Conclusion. Our study will contribute to advancing epidemiological research methods in large-scale prospective cohorts by addressing the challenges posed by COVID-19 mortality as a competing risk. These findings will be particularly valuable to NCI’s Cancer Cohort Consortium and similar cohorts facing analytical challenges due to the ongoing impact of the COVID-19 pandemic.
8 Thu, 09/12/2024 - 03:17 Anonymous 10.208.24.118 Erman Akkus MD MD, Internal Medicine Specialisst, Medical Oncology Fellow erman_akkus@yahoo.com Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Türkiye A Germline Variant of BNIP1 Gene (rs28199) is Associated with Familial Multiple Myeloma
  1. First Name: Timur
    Last Name: Tuncalı
    Degree(s): MD
    Organization: Department of Medical Genetics, Ankara University Faculty of Medicine, Ankara, Turkey
  2. First Name: Hasan Yalım
    Last Name: Akın
    Degree(s): PhD
    Organization: Department of Hematology, Ankara University, Faculty of Medicine, Ankara, Türkiye
  3. First Name: Ayşe
    Last Name: Salihoğlu
    Degree(s): MD
    Organization: Department of Hematology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Türkiye
  4. First Name: Ömür Gökmen
    Last Name: Sevindik
    Degree(s): MD
    Organization: Department of Hematology, Medipol University, Faculty of Medicine, Istanbul, Türkiye
  5. First Name: Hakkı Onur
    Last Name: Kırkızlar
    Degree(s): MD
    Organization: Department of Hematology, Trakya University Faculty of Medicine, Edirne, Türkiye
  6. First Name: Siret
    Last Name: Ratip
    Degree(s): MD
    Organization: Department of Hematology, Acibadem Healthcare Group, Istanbul, Türkiye
  7. First Name: Sevgi
    Last Name: Kalayoğlu Beşışık
    Degree(s): MD
    Organization: Department of Internal Medicine, Division of Hematology, Istanbul University Medical Faculty, Istanbul, Türkiye
  8. First Name: Sibel
    Last Name: Kabukçu Hacıoğlu
    Degree(s): MD
    Organization: Department of Hematology, Pamukkale University Faculty of Medicine, Denizli, Türkiye
  9. First Name: Güldane
    Last Name: Cengiz Seval
    Degree(s): MD
    Organization: Department of Hematology, Ankara University, Faculty of Medicine, Ankara, Türkiye
  10. First Name: Meral
    Last Name: Beksaç
    Degree(s): MD
    Organization: Department of Hematology, Ankara Liv Hospital, Istinye University, Ankara, Türkiye
 Background: A variant in the BNIP1 gene (rs28199) has been reported to be associated with multiple myeloma (MM) risk (Macauda et al., Interlymph-Heidelberg Consortium). We have recently reported that this variant is present in 13 of 18 familial MM cases (72.2%). In this study, we expanded our familial cases to analyze the rs28199 variant and aimed to compare it to non-familial MM and healthy populations.

Methods: A total of 32 familial MM and 30 non-familial MM cases were included in the study from hematology centers in Türkiye. Targeted NGS sequencing was utilized to investigate the germline variant from patients’ peripheral blood samples. Allele frequencies of the study group were compared to the Türkiye Genome Project data.

Results: 65.6% (n=21) of the familial and 40% (n=12) of the non-familial MM cases were positive for the BNIP1 variant, revealing a significant association between the variant and familial MM (OR: 2.86 (95% CI: 1.02-8.04), p=0.04). Among the variant-positive patients, the rates of homozygosity were 47.6% (n=12) in the familial and 8.3% (n=1) in the non-familial MM cases (OR: 10, (95% CI: 1.08-91.98), p=0.02). The variant allele frequencies were 0.48 and 0.22 in familial and non-familial MM cases, respectively (p=0.00). Likewise, rs28199 allele frequency among familial MM cases was also more frequent than the frequency observed within germline whole genome data of healthy population (0.48 vs 0.32, p=0.02).

Conclusion: This study shows that the germline BNIP1 variant (rs28199) when particularly in a homozygous state, is associated with familial MM.
7 Wed, 09/11/2024 - 16:19 Anonymous 10.208.28.69 Armen Byrd Assistant Member MPH, PhD doratha.byrd@moffitt.org Moffitt Cancer Center Characterizing drivers of prognosis and quality of life among Black colorectal cancer survivors: a pooled approach
  1. First Name: Shaneda
    Last Name: Warren Andersen
    Organization: University of Wisconsin-Madison
 Colorectal cancer (CRC) is the second overall leading cause of cancer death in the United States. CRC poses a disproportionate burden among Black individuals, who experience substantially higher recurrence and mortality rates. In the ColoCare cohort, Black CRC survivors had higher risks for mortality, poorer disease-free survival, and differences in potentially clinically actional tumor mutational status. Approaches to improve survivorship outcomes among Black CRC survivors are urgently needed; however, most existing prospective survivorship cohort studies have limited ability to adequately assess potentially actionable drivers of cancer outcomes among this population due to small sample sizes (particularly among ethnic subgroups). To address this gap, we propose to create a forum for collaboration across survivorship cohorts to facilitate deep analyses of the multidimensional aspects of tumor biology and outcomes among Black CRC survivors. To do this, we propose to pool data from Black CRC survivors in existing prospective cohorts to assess the multi-level drivers of survivorship outcomes including 1) tumor molecular profiles; 2) the local and peripheral immune system; 3) intervenable lifestyle exposures; 4) the gastrointestinal microbiome; and 5) social drivers of health. We will leverage the resources of multiple cohorts–including the ColoCare study, the Cancer Genome Atlas, the Southern Community Cohort, the African Caribbean Consortium, and the Detroit Research on Cancer Survivors study, and the Women’s Health Initiative-Life and Longevity After Cancer study– with biospecimens and data collected at diagnosis and afterward. Integration of these cohorts will allow for powerful analyses of predictors of outcomes among Black CRC survivors.
6 Wed, 09/11/2024 - 09:42 Anonymous 10.208.28.69 Cody Watling Postdoctoral Fellow MSc., DPhil. cody.watling@gmail.com National Cancer Institute Circulating per- and polyfluoroalkyl substances and risk of liver cancer: a nested case- control analysis of individual participant data from 12 prospective cohorts
  1. First Name: Jessica
    Middle Initial: L
    Last Name: Petrick
    Degree(s): PhD
    Organization: Boston University
  2. First Name: Barry
    Middle Initial: I
    Last Name: Graubard
    Degree(s): PhD
    Organization: National Cancer Institute
  3. Last Name: Liver Cancer Pooling Project Collaborators
  4. First Name: Dinesh
    Last Name: Barupal
    Degree(s): PhD
    Organization: Icahn School of Medicine at Mount Sinai
  5. First Name: Katherine
    Middle Initial: A
    Last Name: McGlynn
    Degree(s): PhD
    Organization: National Cancer Institute
 Background: Per- and polyfluoroalkyl substances (PFAS) have been associated with numerous deleterious health outcomes including liver damage. However, whether exposure to PFAS is related to liver cancer risk remains unclear.

Methods: We conducted a nested case-control study among 12 prospective cohort studies located in the United States. Pre-diagnostic PFAS, namely perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and perfluorohexanesulfonate (PFHxS), were measured among 853 liver cancer cases and 853 matched control participants. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multivariable-adjusted conditional logistic regression for liver cancer risk by study-specific quartiles of concentrations and per 90th vs. 10th percentile incremental increase.

Results:
In the main multivariable-adjusted model, circulating PFOS, PFOA, and PFHxS concentrations were not associated with liver cancer risk (OR per 90th vs. 10th percentile increase:1.00, 95% CI: 0.79-1.28; 0.92, 0.73-1.15; and 0.95, 0.75-1.21, respectively). However, when analyses were stratified by sex, PFOA concentrations were positively associated with liver cancer risk in males (OR per 90th vs. 10th percentile increase:1.62 95% CI:1.07-2.45), whereas an inverse association was observed amongst females (OR per 90th vs. 10th percentile increase:0.68, 0.50-0.92). Analyses separating liver cancer subtypes, hepatocellular carcinoma (HCC) and intrahepatic
cholangiocarcinoma, showed no evidence of heterogeneity although associations were stronger but not significant for HCC. No evidence of heterogeneity was observed by time to diagnosis, body mass index, alcohol intake, ethnicity, or diabetes status.

Conclusions: In the largest study to date, none of the measured circulating PFAS were associated with liver cancer risk; however, PFOA associations appeared to differ by sex.
5 Wed, 09/11/2024 - 05:15 Anonymous 10.208.24.118 Monireh Sadat Seyyedsalehi Researcher PhD student monireh.seyyedsalehi@studio.unibo.it University of Bologna International Esophageal Squamous Cell Carcinoma Consortium (IESC3)
  1. First Name: Paolo
    Last Name: Boffetta
    Degree(s): M.D.MPH
    Organization: University of Bologna, Stony Brook university
  2. First Name: Michelle
    Last Name: Hanson
    Degree(s): PhD
    Organization: University of Bologna
Background: Esophageal cancer (EC) caused an estimated 511,054 new cases and 445,391 deaths globally in 2022. There are two types: adenocarcinoma (AC) and squamous cell carcinoma (SCC). ESCC is more common globally and is aggressive, affecting the upper and middle parts of the organ, with higher incidence in low- and-middle-income countries, especially Eastern Asia and Eastern and Southern Africa. Due to differences in EC distribution, specific risk factors are being investigated to understand the likelihood of developing this cancer.

Methods: We aim to create the International Esophageal Squamous Cell Carcinoma Consortium (IESC3) to study the epidemiology of ESCC through collaboration with leading research groups worldwide. This consortium will follow successful models like INHANCE for head and neck cancer and StoP for gastric cancer, focusing on large molecular, genetic, and epidemiologic studies. We plan to present it at the NCI-Co-Co to facilitate more collaborative interactions and include additional cohorts, particularly those that have already undergone data harmonization within the Co-Co.

Results: The consortium will focus on researching the various aspects of ESCC, including the role of geographic, demographic, occupational, and environmental factors in its etiology, as well as the impact on mortality, survival, recurrence, and second primary tumors. Additionally, it will explore the genetic determinants of ESCC, assess the effect of screening methods and awareness programs on prevention, and apply novel epidemiological and statistical methods.

Conclusion/Discussion: This consortium will prioritize the involvement of junior investigators alongside experts and serve as a valuable resource for leading research on this specific cancer type.
4 Tue, 09/10/2024 - 17:55 Anonymous 10.208.24.118 Sidney Donzella PhD Candidate MPH sdonzell@fredhutch.org University of Washington; American Cancer Society Sleep measured by accelerometry: Comparing the performance of objective sleep algorithms
  1. First Name: Asuka
    Last Name: Ishihara
    Degree(s): PhD
    Organization: NIDDK
  2. First Name: Antoinette
    Last Name: Rabel
    Degree(s): PhD
    Organization: NIDDK
  3. First Name: Ranganath
    Last Name: Muniyappa
    Degree(s): PhD
    Organization: NIDDK
  4. First Name: Kong
    Middle Initial: Y
    Last Name: Chen
    Degree(s): PhD
    Organization: NIDDK
  5. First Name: Samuel
    Middle Initial: R
    Last Name: LaMunion
    Degree(s): PhD
    Organization: NIDDK
 Background Various algorithms and software are available to score sleep data collected from accelerometer-based wearable sensors. However, little is known about how the combination of algorithms and software may influence the sleep estimates. The aim of this study was to investigate the agreement of sleep constructs scored with different sleep bounding algorithms on two commonly used software platforms (i.e., ActiLife and GGIR). Methods Thirty-five healthy volunteers were invited to wear an ActiGraph wGT3X-BT device for 7 consecutive days and complete a sleep diary. Objective sleep was scored using the count-based Cole-Kripke sleep scoring algorithm and the following sleep bounding algorithms: GGIR heuristic of the distribution in the change in Z-axis angle (HDCZA) with open-source counts, GGIR HDCZA zero crossing counts, GGIR open-source counts with sleep diary, ActiLife Tudor Locke. We included participants who had 16 hours of device wear/day and 4 days of valid device wear. We used intraclass correlation coefficient (ICC) with 95% confidence intervals to assess the agreement of objective sleep constructs with the sleep diary. Results Twenty-nine participants were included. ICC estimates for time asleep and time awake ranged from moderate to good agreement (ICC range 0.53-0.86) for all algorithms compared to the sleep diary. Compared to the sleep diary, all algorithms showed poor agreement for sleep duration (ICC range -0.64-0.47). Conclusion Sleep constructs scored using different algorithms or on different software platforms may not be generalizable to one another. Researchers should use caution when comparing objective sleep measures across studies that used different sleep scoring procedures.
3 Tue, 09/10/2024 - 06:11 Anonymous 10.208.24.118 Hana Zahed PhD zahedh@iarc.who.int International Agency for Research on Cancer (IARC/WHO) Biomarker-based eligibility for lung cancer screening. Validation of the INTEGRAL protein-based risk model in the LC3. Background: Circulating protein biomarkers may improve smoking-based lung cancer risk models. The INTEGRAL-program aimed to identify risk biomarkers within the Lung Cancer Cohort Consortium (LC3), develop a fit-for-purpose protein panel, and train and validate a protein-based model for lung cancer risk assessment.

Methods: Participants had a smoking history and cases were diagnosed with incident lung cancer at most 3 years after blood-draw. We first carried out a proteomics discovery analysis using 731 case-control pairs from six LC3 cohorts and developed the INTEGRAL-panel that includes 21 proteins with non-redundant information on lung cancer risk. The model training and validation phase used the INTEGRAL panel and a case-cohort design (Robbins et al., Ann Epidemiology 2023), including 1,696 incident lung cancers and 2,926 cohort-representatives from 14 LC3 cohorts. Risk models were trained using flexible parametric survival regressions in 7 cohorts, with external validation in the remaining 7 cohorts.

Results: The initial discovery phase identified 36 robust markers of lung cancer risk (LC3, Nat Comm 2023). Preliminary results from the training-cohorts indicate that a protein-based risk model improves risk discrimination compared to the questionnaire-based PLCOm2012 model. Final results from the external validation will be presented at the meeting.

Conclusion/Discussion: Improved lung cancer risk assessment can optimize early detection by better identifying individuals who are likely to benefit from screening. Ongoing efforts within the LC3 consortium include assessing the acceptability and feasibility of using a protein-based risk model to assess eligibility for screening, as well as identifying novel markers in individuals without a smoking history.
2 Fri, 09/06/2024 - 14:03 Anonymous 10.208.28.176 Tamara Litwin Epidemiologist Ph.D., MPH tamara.litwin@nih.gov All of Us Research Program, Office of the Director, National Institutes of Health Lessons Learned from Return of DNA Results in the All of Us Research Program
  1. First Name: Sheri
    Last Name: Schully
    Degree(s): Ph.D.
    Organization: All of Us Research Program, Office of the Director, National Institutes of Health
  2. First Name: Anastasia
    Last Name: Wise
    Degree(s): Ph.D.
    Organization: All of Us Research Program, Office of the Director, National Institutes of Health
 Background
The All of Us Research Program sought to return research DNA results to study participants, including both engaging insights and health-related reports.

Methods
The program obtained Food and Drug Administration (FDA) approval for an investigational device exemption (IDE) to return health-related DNA results. Participants were offered the opportunity to opt into receiving genetic results. Results including genetic ancestry and traits and two health-related reports were returned via a web-based participant portal. Pathogenic and likely pathogenic variant calls were returned through a genetic counseling service and all participants had access to genetic counselors.

Results
There were often extensive delays between sample donation and return of DNA results, taking up to four months to generate reports for significant findings. Over 220,000 All of Us participants have viewed their genetic ancestry report and over 222,000 have viewed any genetic trait report. Over 124,000 participants have viewed their Hereditary Disease Risk report​, of whom ~2% (>2,500) have a pathogenic or likely pathogenic genetic variant in one of 59 included genes. Over 119,000 participants have viewed their Medicine and Your DNA report, of whom 89% (>106,000) have a result that could impact how their body processes one of seven included medications.

Conclusion/Discussion
The DNA results workflow includes many partners and is expensive to maintain and update. The FDA IDE delays changes to the protocol. Participants value DNA results and have high expectations for return of personalized results from All of Us.
1 Wed, 08/07/2024 - 17:23 Anonymous 10.208.28.122 Ping-Ching Hsu Associate Professor Ph.D., M.Sc. PHsu@uams.edu University of Arkansas for Medical Sciences Genome-wide DNA methylation landscape is associated with arsenic exposure in Arkansas Rural Community Health (ARCH) study
  1. First Name: Michael
    Last Name: Bauer
    Degree(s): PhD
    Organization: University of Arkansas for Medical Sciences
  2. First Name: Shelbie
    Middle Initial: D
    Last Name: Stahr
    Degree(s): PhD, MPH
    Organization: University of Arkansas for Medical Sciences
  3. First Name: Lora
    Middle Initial: J
    Last Name: Rogers
    Degree(s): MS
    Organization: University of Arkansas for Medical Sciences
  4. First Name: Gail
    Middle Initial: A
    Last Name: Runnels
    Degree(s): RN
    Organization: University of Arkansas for Medical Sciences
  5. First Name: L
    Middle Initial: Joseph
    Last Name: Su
    Degree(s): PhD, MPH
    Organization: UT Southwestern Medical Center
 Environmental stressors have been shown to alter DNA methylation that can serve as an important step in response to environmental stimuli and the onset of disease. However, little is known about the epigenetic modifications from arsenic exposure, especially in the rural state where cancer incidence and mortality is high. 134 salivary DNA samples were randomly selected from participants in the Arkansas Rural Community Health (ARCH) study where more than 26,000 women from all 75 counties in Arkansas contributed saliva samples and a short baseline questionnaire on breast cancer risk. Arsenic levels were quantified using the inductively coupled plasma mass spectrometry (iCAP RQ ICP-MS). DNA samples were processed and assayed for genome-wide DNA methylation profiles using the Illumina Infinium MethylationEPIC 850K array. R package CpGassoc was used to identify probes that are significantly associated with arsenic levels. Using the relative beta values, we identified the top 100 probes associated with high (top 15%) salivary arsenic concentrations when compared with low (bottom 85%) concentrations among 134 ARCH participants, with 5 genes hypermethylated and 15 genes hypomethylated including the pro-apoptotic gene TP53AIP1. When the participants were stratified by breast cancer diagnosis, arsenic levels were significantly higher among breast cancer patients than healthy participants were. Heavy metals are endocrine disruptors with the ability to induce epigenetic aberration. Here we demonstrated the strong correlation of epigenetic alterations from arsenic exposure. Further study is needed to understand mechanisms underlying those changes to address the environmental exposure and cancer incidence in rural communities, especially on early-onset cancers.